NCT00325767View on ClinicalTrials.gov

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

September 30, 2005

Conditions
Mucociliary Clearance
Interventions
DRUG

nebulized albuterol (2.5 mg/3ml/dose)

DRUG

nebulized levalbuterol (1.25 mg/3ml/dose)

DRUG

nebulized placebo (3ml/dose)

Trial Locations (1)

21287

Eudowood Division of Pediatric Respiratory Sciences, Baltimore

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT00325767 - Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol | Biotech Hunter | Biotech Hunter